Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


PharmaVentures Acts as Exclusive Advisor to Sanofi in the Divestment of Zentiva's Hlovovec Production Facility to Wood Pharma Holding

OXFORD, England, December 19, 2012 /PRNewswire/ --

PharmaVentures is pleased to announce that it has acted as transaction advisors and sale process executioners for Sanofi. The current deal covers Sanofi's divestment of its Zentiva subsidiary's production plant in Hlohovec, Slovakia. Under the terms of this agreement, Sanofi will sell to Wood Pharma Holding the production, packaging and distribution part of its Zentiva business covering Active Pharmaceutical Ingredients (APIs) and Drug Products activities. The sale includes transfer of the production facilities and employees. Future co-operation in the purchase of drug products and APIs produced by Wood Pharma Holding in Hlohovec in the next five years has also been agreed.

This divestment follows the 2010 sale of Sanofi's two European facilities (Porcheville, France and Alnwick, United Kingdom) to Covance where PharmaVentures acted as exclusive advisors to Sanofi. .

PharmaVentures continues to strengthen its considerable experience in the M&A field including divestments of manufacturing and R&D businesses. Fintan Walton, CEO, PharmaVentures Ltd said: "PharmaVentures is delighted to have worked with Sanofi again in finding a new buyer for one of their facilities. This is a fantastic outcome for the Hlohovec site and for the Slovakian Pharmaceutical industry as a whole. Not only does this deal safeguard jobs at Hlohovec, but it offers the prospect of expansion of the existing business and further job opportunities for the region."

Over the past 21 years, PharmaVentures has acted as advisor to over 600 global pharmaceutical and biotechnology clients in transactions covering licensing, merger, acquisition, divestment and joint venture activities for companies.

 

About PharmaVentures

PharmaVentures is a premier transaction advisory boutique; a world leader in partnering, M&A deals and strategic alliances. Our unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes us uniquely placed to support your business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

Find out more http://www.pharmaventures.com

Our services include:

  • M&A (divestments, mergers, acquisitions and strategic transactions)
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
  • Licensing (in and out licensing)
  • Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)

Now in its 21st year, PharmaVentures is based in Oxford, UK, and employs over 17 people.

 

For further information, contact:
Dr Fintan Walton
CEO
PharmaVentures Ltd
+44-1865-332700
enquiries@pharmaventures.com

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
Satisfying customers and winning their loyalty is the foundation that every successful business is built upon. Delivering a consistently excellent experience builds a level of customer intimacy that will set your business apart from the competition. Consider that 80% of your company’s ...
In 2017, word-of-mouth marketing will be a lucrative strategy and should allow small businesses and startups to carve out powerful niches in a marketplace that's noisier than ever. When was the last time you paused to consider the noise on the internet? If you really take a look, it’s...
Serverless Computing or Functions as a Service (FaaS) is gaining momentum. Amazon is fueling the innovation by expanding Lambda to edge devices and content distribution network. IBM, Microsoft, and Google have their own FaaS offerings in the public cloud. There are over half-a-dozen op...
2016 was a year of dips and dives, twists and turns. Judging by the first couple of weeks of the new year, it’s reasonable to expect 2017 will be another roller coaster year for providers, patients, suppliers and payers. As president and CMO of LeanTaaS, a growth-stage innovator of clo...
There is no more effective way to reduce your overall test environment spend than to migrate to cloud test environments and embrace testing and infrastructure automation. The nature of test environments is inherently temporary—you set up an environment, run through an automated test su...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE